ScreenerHero

AVTX Avalo Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · avalotx.com
13.68USD+0.66%Mkt Cap: 728.83M $P/E: —

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap728.83M USD
Enterprise Value328.80M USD
Revenue (TTM)59.00K USD
Gross Profit59.00K USD
Net Income (TTM)-78.26M USD
Revenue/Share0.0020 USD
Last Price13.68 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.02
PEG—
EV/EBITDA-3.60
EV/Revenue5572.84
P/S12353.08
P/B1.60
EPS (TTM)-4.31
EPS (Forward)-2.71
52W Range
10.7022% of range24.27
52W High24.27 USD
52W Low10.70 USD
Profitability
Gross Margin100.00%
Oper. Margin-154847.45%
EBITDA Margin0.00%
Profit Margin-132642.37%
ROE-94.23%
ROA-67.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.46M USD
CapEx (TTM)—
FCF Margin-39442.37%
FCF Yield-3.19%
Net Debt-400.03M USD
Net Debt/EBITDA4.38
Balance Sheet
Debt/Equity0.00
Current Ratio19.31
Quick Ratio18.94
Book Value/Sh8.48 USD
Cash/Share7.46 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:240
Split DateDec 29, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.08 USD
Upside (mean)+222.2%
Target Range30.00 USD – 60.00 USD
30.00+222.2% to mean60.00
# Analysts12
Ownership
Shares Out.53.63M
Float40.11M
Insiders1.69%
Institutions133.73%
Short Interest
Short Ratio14.3d
Short % Float24.14%
Short % Out.24.10%
Shares Short12.93M
Short (prev mo.)13.09M
Technical
SMA 5018.08 (-24.3%)
SMA 20016.71 (-18.1%)
Beta0.69
S&P 52W Chg16.45%
Avg Vol (30d)1.03M
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)29.0
MACD-1.0802
MACD Signal-0.9215
MACD Hist.-0.1587
BB Upper19.14 USD
BB Middle16.13 USD
BB Lower13.12 USD
BB Width37.32%
ATR (14)1.001 USD
Vol Ratio (20d)0.81x